Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
159.50
-6.84 (-4.11%)
At close: Mar 11, 2026, 4:00 PM EDT
159.51
+0.01 (0.01%)
After-hours: Mar 11, 2026, 7:35 PM EDT
Axsome Therapeutics Revenue
In the year 2025, Axsome Therapeutics had annual revenue of $638.50M with 65.55% growth. Axsome Therapeutics had revenue of $196.00M in the quarter ending December 31, 2025, with 65.03% growth.
Revenue (ttm)
$638.50M
Revenue Growth
+65.55%
P/S Ratio
12.78
Revenue / Employee
$690,266
Employees
925
Market Cap
8.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 638.50M | 252.80M | 65.55% |
| Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
| Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
| Dec 31, 2022 | 50.04M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Halozyme Therapeutics | 1.40B |
| Bio-Techne | 1.22B |
| Arrowhead Pharmaceuticals | 1.09B |
| Krystal Biotech | 389.13M |
| ImmunityBio | 113.29M |
| Cytokinetics | 88.04M |
| Praxis Precision Medicines | 7.46M |
| ABIVAX Société Anonyme | 6.23M |
AXSM News
- 1 day ago - Axsome Therapeutics, Inc. (AXSM) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 14 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 16 days ago - Axsome: Q4 Earnings Review: Solid Performance, But Pipeline May Be Overvalued - Seeking Alpha
- 16 days ago - Axsome Therapeutics, Inc. (AXSM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 22 days ago - Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd. - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23 - GlobeNewsWire
- 6 weeks ago - Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline - Seeking Alpha